|Videos|December 22, 2019
Treating HER2-Positive Metastatic Breast Cancer: DESTINY-Breast02 and DESTINY-Breast03
Author(s)Sponsored Content
The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.
Advertisement
The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
6 Cancer Drugs FDA Approved in August 2026 and What They Mean for You
2
What Breast Cancer Survivors Should Know About Weight Loss and Long-Term Health
3
Diagnosed With Ovarian Cancer at 15: 10 Things That Helped Brynn Forlizzi Through Treatment
4
Lung Cancer Patient Shares How Community, Hope and Self-Advocacy Helped Her Through Treatment
5